“When there is approval for HIV or another indication, can the drug be prescribed off label for other indications such as NASH and other illnesses.”

Yes, but off label prescriptions won’t be significant enough to produce any real revenue. Remember that insurance companies have to approve off label prescriptions and a drug that costs $1,500 or so per vial will not be an easy sell for insurance companies. Additionally, doctors will need to be educated on the MOA of leronlimab and potential indications, which will take time.